Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in Newly Diagnosed Intermediate- and High-risk AML
NCT06928376Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Apr 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of venetoclax in acute myeloid leukemia (AML) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Composite Complete Remission Rate at 1 month. Started Apr 2024; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06928376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06928376.